Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003 works as designed to address the underlying immune suppression observed in metastatic RCC patients, while also generating a highly specific and durable T-cell response that appears to improve clinical outcomes in terms of PFS, when combined with sunitinib," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "This is the first prospective analysis of immunodynamics in RCC patients receiving sunitinib in combination with an immunotherapy, and we plan to confirm these positive results in a randomized setting in a Phase 3 clinical trial."

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com

Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com


'/>"/>
SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... registered the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... With the opioid epidemic now ... excessive levels of alcohol use. Alcohol and its misuse causes long-term consequences for ... the susceptibility to strokes in those 65 years and older. In addition, there ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... process that selects DNA or RNA from a random library of sequences depending ... used as drugs or diagnostic agents. SELEX selection is commonly performed using filters, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... hired award-winning creative director Joe Ferrazano to serve in the newly created position ... will be overseeing the agency’s creative efforts in the Chicago and LA offices. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car ... anxiety. "Pet owners often think anxiety only manifests itself as trembling or ‘tail ... ways, and there’s things that be done about it,” says Dr. Jim Lowe, technical ...
Breaking Medicine News(10 mins):